Zhong Ji Longevity Science Group Limited (HK:0767)
:0767
Want to see HK:0767 full AI Analyst Report?
Top Page
Zhong Ji Longevity Science Group Limited
(0767)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$0.42
▼(-17.25% Downside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by weak fundamentals (sustained losses, compressed margins, and negative operating/free cash flow), reinforced by bearish technicals with the price below all key moving averages and negative MACD. Low leverage provides some balance-sheet support, but the negative P/E reflects ongoing unprofitability and limits valuation support.
Positive Factors
Low leverage / conservative balance sheet
The extremely low debt-to-equity profile materially reduces refinancing and solvency risk over the medium term. A light leverage position preserves liquidity optionality, allowing management time and flexibility to implement restructuring, invest selectively, or raise growth capital without acute pressure.
Negative Factors
Sustained negative operating and free cash flow
Consecutive years of negative operating and free cash flow materially weaken liquidity and increase reliance on reserves or external funding. Persistent cash burn constrains reinvestment and strategic flexibility, raising risk that the firm must take dilutive or costly financing if performance does not stabilize.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative balance sheet
The extremely low debt-to-equity profile materially reduces refinancing and solvency risk over the medium term. A light leverage position preserves liquidity optionality, allowing management time and flexibility to implement restructuring, invest selectively, or raise growth capital without acute pressure.
Read all positive factors
Zhong Ji Longevity Science Group Limited (0767) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$280.13M
Dividend YieldN/A
Average Volume (3M)487.89K
Price to Earnings (P/E)―
Beta (1Y)-0.12
Revenue Growth-1.54%
EPS Growth53.76%
CountryHK
Employees55
SectorFinancial
Sector Strength70
IndustryFinancial - Credit Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding636,654,300
10 Day Avg. Volume325,210
30 Day Avg. Volume487,892
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)0.75
Price to Sales (P/S)1.80
P/FCF Ratio-12.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhong Ji Longevity Science Group Limited Business Overview & Revenue Model
Company Description
Zhong Ji Longevity Science Group Limited operates as an investment holding entity, engaging in a broad spectrum of commercial endeavors. Its operations include providing money lending solutions across Hong Kong and Mainland China. The company's he...
How the Company Makes Money
null...
Zhong Ji Longevity Science Group Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 165.18M | 168.63M | 64.99M | 89.44M | 62.98M |
| Gross Profit | 16.74M | 57.41M | 56.28M | 79.41M | 49.40M |
| EBITDA | -7.37M | -23.10M | 13.02M | 15.99M | 16.13M |
| Net Income | -16.75M | -34.73M | 2.31M | -904.00K | 6.05M |
Balance Sheet | |||||
| Total Assets | 499.91M | 525.63M | 509.25M | 484.84M | 517.50M |
| Cash, Cash Equivalents and Short-Term Investments | 24.30M | 47.84M | 81.08M | 60.07M | 19.44M |
| Total Debt | 5.57M | 19.11M | 20.20M | 11.76M | 12.93M |
| Total Liabilities | 74.92M | 125.49M | 78.79M | 63.99M | 46.78M |
| Stockholders Equity | 397.56M | 373.42M | 403.40M | 393.83M | 443.75M |
Cash Flow | |||||
| Free Cash Flow | -23.13M | -61.76M | 15.28M | 11.08M | -40.51M |
| Operating Cash Flow | -23.12M | -61.05M | 15.28M | 12.11M | -39.62M |
| Investing Cash Flow | -23.03M | 11.47M | 382.00K | 16.59M | 2.91M |
| Financing Cash Flow | 24.70M | 15.17M | 6.02M | -7.45M | 3.44M |
Zhong Ji Longevity Science Group Limited Technical Analysis
Neutral
0.51
Price Trends
0.43
Positive
0.46
Negative
0.51
Negative
Market Momentum
<0.01
Negative
54.06
Neutral
82.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0767, the sentiment is Neutral. The current price of 0.51 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.43, and above the 200-day MA of 0.51, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.06 is Neutral, neither overbought nor oversold. The STOCH value of 82.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0767.
Zhong Ji Longevity Science Group Limited Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
47 Neutral | HK$46.29M | 17.69 | 0.81% | ― | -8.47% | 88.98% | |
47 Neutral | HK$229.50M | 194.65 | 3.83% | ― | 28.38% | ― | |
46 Neutral | HK$80.15M | -3.01 | -4.97% | ― | -31.23% | 33.60% | |
42 Neutral | HK$280.13M | -20.72 | -4.17% | ― | -1.54% | 53.76% | |
42 Neutral | HK$1.61B | -23.33 | -21.86% | ― | -23.87% | -71.21% | |
42 Neutral | HK$131.58M | -2.37 | -13.09% | ― | -6.60% | 80.94% |
* Financial Sector Average
HK:0767
Zhong Ji Longevity Science Group Limited
0.44
-0.04
-8.33%
HK:1660
Zhaobangji Properties Holdings Limited
0.26
0.13
94.03%
HK:0736
China Properties Investment Holdings Limited
0.25
0.11
78.57%
HK:8019
Hao Wen Holdings Ltd.
0.13
-0.13
-50.00%
HK:8223
Ziyuanyuan Holdings Group Ltd.
0.26
-1.40
-84.55%
HK:8525
Baiying Holdings Group Ltd.
0.85
0.00
0.00%
Zhong Ji Longevity Science Group Limited Corporate Events
Zhong Ji Longevity Science Delays Circular on Asian Cell Lab Acquisition
Jun 10, 2026
Zhong Ji Longevity Science Group Limited is a Bermuda-incorporated company listed in Hong Kong that focuses on longevity-related science and healthcare businesses. The group is pursuing strategic investments in advanced biomedical operations, incl...
Zhong Ji Longevity Science Group Sets 2026 AGM to Approve Accounts, Board and Share Mandate
Jun 8, 2026
Zhong Ji Longevity Science Group Limited has called its annual general meeting for 30 June 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements and directors’ and auditors’ reports for the yea...
Zhong Ji Longevity Science Delays Circular on Cell Lab Stake Acquisition
Apr 30, 2026
Zhong Ji Longevity Science Group Limited has announced a further delay in sending a shareholder circular regarding its planned major and connected transaction to acquire 25% of Asian Integrated Cell Laboratory Limited through the issue of converti...
Zhong Ji Longevity Science Forms AI Vision Health Joint Venture in China
Apr 13, 2026
Zhong Ji Longevity Science Group has formed a joint venture in mainland China between its wholly owned unit Shenzhen Zhong Ji Health Science and Guangdong Liangjingjing Technology, a specialist in AI-based eye health founded in 2023. Zhong Ji Heal...
Zhong Ji Longevity Science Group Further Delays Circular on Cell Lab Stake Acquisition
Apr 8, 2026
Zhong Ji Longevity Science Group Limited has announced a further delay in sending a shareholder circular related to its planned acquisition of 25% of Asian Integrated Cell Laboratory Limited, a major and connected transaction that will be funded t...
Zhong Ji Longevity Advances IP Transfer to Clear Key Condition for Stem Cell Unit Acquisition
Apr 2, 2026
Zhong Ji Longevity Science Group Limited has updated investors on conditions tied to its planned acquisition of 25% of Asian Integrated Cell Laboratory Limited, to be settled via the issue of convertible notes. The deal hinges on the transfer of k...
Zhong Ji Longevity Narrows 2025 Loss Despite Margin Pressure
Mar 26, 2026
Zhong Ji Longevity Science Group Limited reported a slight 2.7% decline in revenue to HK$161.8 million for 2025, while gross profit more than halved due to higher costs. Despite this pressure on margins, the group’s net loss narrowed by abou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.